Back to Browse Journals » Drug Design, Development and Therapy » Volume 4

Current and developing therapeutic agents in the treatment of Chagas disease

Authors Werner Apt

Published Date September 2010 Volume 2010:4 Pages 243—253


Published 17 September 2010

Werner Apt
University of Chile, Faculty of Medicine, Santiago, Chile

Abstract: Chagas disease must be treated in all its stages: acute, indeterminate, chronic, and initial and middle determinant chronic, due to the fact that DNA of the parasite can be demonstrated by PCR in chronic cases, where optical microscopy does not detect parasites. Nifurtimox (NF) and benznidazole (BNZ) are the drugs accepted to treat humans based upon ethical considerations and efficiency. However, both the drugs produce secondary effects in 30% of the cases, and the treatment must be given for at least 30–60 days. Other useful drugs are itraconazole and posaconazole. The latter may be the drug to treat Chagas disease in the future when all the investigations related to it are finished. At present, there is no criterion of cure for chronic cases since in the majority, the serology remains positive, although it may decrease. In acute cases, 70% cure with NF and 75% with BNZ is achieved. In congenital cases, 100% cure is obtained if the treatment is performed during the first year of life. In chronic acquired cases, 20% cure and 50% improvement of the electrocardiographic changes are obtained with itraconazole.

Keywords: Chagas disease, treatment, nifurtimox, benznidazole, allopurinol, itraconazole, posaconazole

Download Article [PDF] 

Creative Commons License This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution - Non Commercial (unported, v3.0) License. The full terms of the License are available at Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. Permissions beyond the scope of the License are administered by Dove Medical Press Limited. Information on how to request permission may be found at:

Readers of this article also read:

Insight into 144 patients with ocular vascular events during VEGF antagonist injections

Mansour AM, Shahin M, Kofoed PK, Parodi MB, Shami M, Schwartz SG

Clinical Ophthalmology 2012, 6:343-363

Published Date: 6 March 2012

Cytotoxicity patterns of arsenic trioxide exposure on HaCaT keratinocytes

Udensi UK, Graham-Evans BE, Rogers CS, Isokpehi RD

Clinical, Cosmetic and Investigational Dermatology 2011, 4:183-190

Published Date: 9 December 2011

Fungus-mediated biological synthesis of gold nanoparticles: potential in detection of liver cancer

Chauhan A, Zubair S, Tufail S, Sherwani A, Sajid M, Raman SC, Azam A, Owais M

International Journal of Nanomedicine 2011, 6:2305-2319

Published Date: 12 October 2011

Facial transplantation: a review of ethics, progress, and future targets

Edwards JA, Mathes DW

Transplant Research and Risk Management 2011, 3:113-125

Published Date: 5 September 2011

Drug discovery and development for neglected diseases: the DNDi model

Eric Chatelain, Jean-Robert Ioset

Drug Design, Development and Therapy 2011, 5:175-181

Published Date: 16 March 2011

Development, clinical utility, and place in therapy of posaconazole for prevention and treatment of invasive fungal infections

Emily Zoller, Connie Valente, Kyle Baker, et al

Drug Design, Development and Therapy 2010, 4:299-311

Published Date: 4 November 2010

Update on the clinical utility of sildenafil in the treatment of pulmonary arterial hypertension

Gautam V Ramani, Myung H Park

Drug Design, Development and Therapy 2010, 4:61-70

Published Date: 6 May 2010

Continuation treatment of major depressive disorder: is there a case for duloxetine?

Trevor R Norman, James S Olver

Drug Design, Development and Therapy 2010, 4:19-31

Published Date: 12 February 2010

Imaging of peripheral vascular disease

Mo Al-Qaisi, David M Nott, David H King, Sam Kaddoura, Mo Hamady

Reports in Medical Imaging 2009, 2:25-34

Published Date: 27 March 2009